Summary: Despite the hepatic arterial infusion chemotherapy (HAI) has been advocated as an effective therapy for hepatocellular carcinoma (HCC) with multiple intrahepatic metastases, Chemosensitivity of HCC for HAI with multidrug regimen has not been sufficiently investigated. The purpose of this study was to evaluate the in vitro chemosensitivity of HCC using 3-(4,5-dimethylthiazol-2-yl)-2, 5-Biphenyl-2H tetrazolium bromide (MTT) assay with the combinations of various antitumor drugs, and compared with the clinical results of HAI for patients with multiple intrahepatic recurrences of HCC. To evaluate the in vitro Chemosensitivity of HOC to the combinations of antitumor drugs, 54 resected specimens of HCC were assayed using MTT assay with seven antitumor agents, 5-fluorouracil (5-FU), mitomycin C (MMC), adriamycin (ADM), etoposide (VP-16), cisplatin (CDDP), methotrexate (MTX) and CPT-11 (SN-38), exposed singly, or in combination. The data were compared with the clinical results of HAI for patients who manifested the multiple intrahepatic recurrence. In addition, the in vitro combined effect of CDDP and 5-FU for human hepatocellular carcinoma cell, KYN-1 and KYN-2, was analysed quantitatively. Of 54 resected specimens, 40 specimens assayed successfully, and an increased in vitro chemosensitivity of HCC when treated with combinations of antitumor drugs was observed: single drug 12.2%, two drugs combined 50.9% and three drugs combined 67.0%. The results of in vitro assay were well correlated, 85.7% in predicting accuracy, with the clinical results of 14 patients who underwent HAI for multiple recurrence of HCC, and also correlated with the experimental results of the combined use of CDDP and 5-FU in KYN-1 and KYN-2 in terms of pharmacokinetic reactions, i.e. synergism or antagonism. The MTT assay with the combinations of antitumor drugs represents an informative chemosensitivity test to HAI with multidrug regimen for recurrence of HOC.
INTRODUCTION
H epatocellular carcinoma (HCC) is the most common lethal malignancy in the world. While hepatic resection or liver transplantation only offers a chance of cure, resection was possible in less than a third of all patients with HCC, and the recurrence rate after surgery including both resection and liver transplantation is high in advanced cases [1] [2] [3] . Furthermore, 28.7 to 45.0% of the intrahepatic recurrence after resection manifested multiple nodules in the remnant liver, and sometimes with widespread distribution [2, 4, 5] . HCC with multiple widespread intrahepatic metastases is a devastating condition not amenable to various therapeutic modalities [2,6-8]. Although systemic chemotherapy has been of little value in contributing to survival benefit [9-11 ], hepatic arterial infusion chemotherapy (HAI) using an implantable reservoir has been advocated as an effective therapy to improve the prognosis of inoperable HCC [1, [12] [13] [14] . Okuda et al. [14] reported that 71.0% overall response rate was achieved in patients with postoperative multiple recurrence of HCC using HAI with low dose administration of cisplatin and 5-fluorouracil (FP-HAI), however, only the patients who showed complete response could receive survival benefit, comparing with other patients whose responses were categorized in partiel response, no change or progressive disease. Therefore, even though HAI may be an effective modality for postoperative multiple recurrence of HCC, the individual appropriate regimen of antitumor drugs and/or patient selection with the aim of the complete response would be necessary.
The rapid colorimetric assay described by Mosmann [15] for determining cell viability is measured by cell ability to convert soluble tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2, 5-Biphenyl-2H tetrazolium bromide (MTT), to insoluble colored formazan. The MTT assay for chemosensitivity testing is a rapid and semi-automated quantitative assay, and has been used for screening the effects of antitumor agents on several cell lines [16] . Moreover, a better appreciation of the usefulness of the MTT assay as a predictive method for appropriate individual chemotherapy has been gained in treatments for leukemia [17] , gastric cancer [1 8 ] or colorectal cancer [19] .
However, with regard to the combination chemotherapy that is clinically used in common, there have been no simple and rapidly informative chemosensitivity tests so far and little has been known about chemosensitivity of HCC. The purpose of this study was to evaluate the in vitro chemosensitivity of HCC using MTT assay with the combinations of various antitumor drugs, and compared with the clinical results of HAI for patients with multiple intrahepatic recurrences of HCC. In addition, we described an example of experimental chemotherapy and a quantitative analysis of the combined effect of CDDP and 5-FU for human HCC cell lines, which results were well correlated with that of MTT assay with the combinations of antitumor drugs. 
MATERIALS AND METHODS

IR (%)=[1-(T-B)/(C-B)] X100
where Efficacy rates of antitumor drugs used singly or in combination of two or three drugs. An increased in vitro chemosensitivity of HCC when treated with combinations of antitumor drugs was observed. The changes in efficacy rates of single drug, two drugs combined and three drugs combined of each drug were as follows: CDDP, 20.0%-55.0%-62.5%; VP-16,0%-48.3%-58.6%; SN-38 (CPT-l 1), 0%-54.5%-72.7%; ADM, 30.0%-57.5%-65.0%; MMC, 17.5%-57.5%-65.0%; 5-FU, 12.5%-40.0%-65.0%; MTX, 5.4%-37.8%-73.0%. Although 86.4% of drugs assayed singly was judged ineffective, conversion rate, i.e. the rate of drugs defined as 'ineffective' by single drug assay converted to 'effective' when combined with another drug, averaged out at 45.1%: the conversion rates of CDDP, ADM, VP-16, 5-FU, MTX, MMC and SN-38 (CPT-11) were 50.0%, 60.0%, 48.6 %, 42.8%, 32.4%, 51.5% and 54.5%, respectively.
P=Q=1
. CI values that are smaller than, equal to, or greater than 1, represent synergism, summation and antagonism, respectively.
RESULTS
Chemosensitivity of specimens obtained from surgery
Forty of 54 specimens (74.1%) were successfully assayed and analyzed in this study. The reason for all the 14 unsuccessful assays was an insufficient amount of viable cells in control. Each efficacy rate of the seven antitumor drugs using the MTT assay was shown in Fig. 1 . The effective drug combinations were listed in Table 1 .
Analysis of correlation between the clinical results of HAI for intrahepatic recurrence and the chemosensitivity determined by the MTT assay for the primary HCC.
Characteristics of 14 patients who had undergone resection of primary HCC followed by the MTT 
DISCUSSION
One of the reasons why chemosensitivity testing has not been incorporated into standard oncologic therapy has been the lack of a good drug sensitivity assay for combination chemotherapy that has been commonly used in the clinical setting. A number of studies concerning the combined effect, i.e., synergism, summation or antagonism, of several antitumor drugs on fresh human tumor specimens or established cell lines have been reported and it has been confirmed that there exists individual diversity not only in the chemosensitivity but even in the combined effect of various antitumor drugs [17, [28] [29] [30] . However, a simple method suitable for screening individual combined effects has not yet been developed. Morabito et al. [17] asserted that the MTT assay is suitable for evaluating the in vitro chemosensitivity of chronic lymphocytic leukemia (CLL) B-cells to 'multidrug regimen compounds'. Thus, we made a hypothesis that MTT assay with antitumor drugs combined may reflect the combined effect of the solid malignant tumor and this study was undertaken. Preliminary results of our study, however, showed a high compatibility of 85.7% in predicting accuracy, i.e., coincidence of the results of MTT assay and the clinical effects of corresponding HAT chemotherapy.
Morabito et al. [17] also reported that a synergistic effect was observed in vitro when CLL B-cells obtained from patients were simultaneously exposed to those antitumor drugs that showed ineffectiveness in single use, such as vincristine, prednisone or epirubicin. Our study indicated that the greater the number of drugs combined, the higher each efficacy rates of drugs increased, as is the advantageous principle of the combination chemotherapy in clinical use. In addition, 45.1% of the drugs in single use evaluated 'ineffective' were converted to those `e ffective' when used in combination with another drug. Therefore, it is suggested that the combined use of 'ineffective' drugs does not necessarily mean the 'ineffective' drug combination and the chemosensitivity tests so far might neglect the efficacy of combined use of those drugs evaluated 'ineffective'.
There have been many controversies concerning the differences in chemosensitivity between primary tumors and their metastases [31] [32] [33] [34] . Kurihara et al. [34] reported that a chemosensitivity assay of primary gastric cancer was useful for evaluating the effectiveness of antitumor agents for arterial infusion or systemic chemotherapy against liver metastasis. Kusuzaki et al.
[32] also reported that regardless of whether the pulmonary metastatic tumors of osteosarcoma were synchronous or metachronous, they showed the same change in their DNA ploidy our study, multiple intrahepatic recurrences of 14 patients who underwent HAT occurred within three years after surgery and those recurrence patterns were considered to be metastatic tumors rather than multicentric occurrence on the basis of several diagnostic images [5, 35] , and the outcomes of HAI were significantly correlated with the results of the MTT assay for primary tumor. Therefore, it is possible that intrahepatic metastases may bear the inherent nature of chemosensitivity of the primary tumor unless any chemotherapy was conducted during the period between surgical resection and subsequent intrahepatic metastases.
One of the pharmacokinetic advantages of HAI is the locoregional delivery with a high concentration of antitumor drugs. Cancer cell in monolayer chemosensitivity assay under PPC drug concentration setting are exposed to a high concentration of antitumor drugs, therefore, this assay may be similar to the internal environment of the liver receiving the administration of HAT. Link et al. [36] reported that the human tumor colony-forming assay indicated high predictive accuracy, 86%, for the effectiveness of HAI against various liver tumors, and also described that the high drug concentration chosen in their study could be achieved in the clinical HAT. The drug concentration in this study and the results obtained were similar to those of Link et al. [36] .
In this study, the combinations of drugs tested were determined in an arbitrary fashion. Even though the majority of drug combinations were not associated with those in common clinical use and a practical regimen based on the results of MTT remains unclear, a brand-new modulation of conventional drugs could be created from the results of MTT.
In conclusion, the preliminary results of this study suggest that the MTT assay in PPC setting may become a simple and rapidly informative chemosensitivity test for HAT against multiple intrahepatic recurrences of HCC, providing individualized chemosensitivity assessments for HAT with combination chemotherapy regimens. However, a prospective study is needed to clarify the efficacy of our assay for HAT against multiple intrahepatic recurrence of HCC. 
